Sopharma AD

SFA

BG11SOSOBT18

Drug Retailers

End-of-day quote Bulgaria S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.04 ^BGN	+1.34%		0.00%	+5.59%

Feb. 29	Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Sopharma AD Reports Sales Results for the Month and Eleven Months Ended November 2023	CI

Sopharma : Insider information

October 09, 2023 at 09:46 am EDT

Insider information 09.10.2023 08:35:07 (local time)

Company: Sopharma AD-Sofia (SFA)

As a result of the capital increase of Sopharma AD through the exercise of warrants, ISIN BG9200001212, the new company's capital amount of BGN 172,590,578 is entered in the Commercial Register.

The entire piece of news is available in English on the financial website X3News.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Sopharma AD published this content on 09 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2023 13:45:25 UTC.

Latest news about Sopharma AD

Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Sopharma AD Reports Sales Results for the Month and Eleven Months Ended November 2023	Dec. 20	CI
Sopharma AD commences an Equity Buyback Plan under the authorization approved on August 4, 2023.	Dec. 04	CI
Sopharma AD Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30	CI
Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024	Nov. 24	CI
Sopharma Ad Proposes Distribute Dividend for First Half 2023	23-10-03	CI
Sopharma AD acquired additional 5.01% minority stake in Sopharma Buildings REIT-Sofia (BUL : SFB).	23-09-27	CI
Sopharma AD Reports Sales Results for the Month and Eight Months Ended August 2023	23-09-20	CI
Sopharma AD acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.	23-09-04	CI
Sopharma AD announced that it expects to receive ?30 million in funding	23-08-30	CI
Sopharma AD Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Sopharma AD Reports Sales Results for the Month and First Half Ended June 2023	23-07-20	CI
Sopharma AD signed an agreement to acquire Pharmanova d.o.o.	23-07-13	CI
Sopharma AD Reports Sales Results for the Month and Year to Date Ended May 2023	23-06-20	CI
Sopharma AD's Equity Buyback announced on June 5, 2018, has expired.	23-06-03	CI
Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023	23-06-02	CI
Sopharma AD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Sopharma AD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Sopharma AD Reports Sales Results for the Month and Year to Date Ended February 2023	23-03-20	CI
Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Sopharma AD Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
An unknown buyer acquired a 4.121376% stake in Sopharma AD from Telso AD for BGN 22.5 million.	23-02-21	CI
Donev investments holding AD completed the acquisition of additional 8.16% stake in Sopharma AD (BUL : SFA) for BGN 44.6 million.	23-02-16	CI
Sopharma AD Provides Sales Results for the Month of January 2023	23-02-06	CI
Donev investments holding AD made an offer to acquire 8.16% stake in Sopharma AD for BGN 49.5 million.	23-01-12	CI

Chart Sopharma AD

Duration

Period

More charts

Company Profile

Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.

Sector

Drug Retailers

Calendar

2024-05-19 - April 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.04 BGN

Average target price

7.14 BGN

Spread / Average Target

+18.21%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
SOPHARMA AD	+5.59%	546M
WALGREENS BOOTS ALLIANCE, INC.	-31.77%	15.27B
JD HEALTH INTERNATIONAL INC.	-29.67%	10.84B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-28.54%	6.06B
YIFENG PHARMACY CHAIN CO., LTD.	+8.14%	6.04B
MATSUKIYOCOCOKARA & CO.	-11.41%	5.86B
NAHDI MEDICAL COMPANY	-1.17%	4.69B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+52.19%	4.29B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-14.86%	3.33B
WELCIA HOLDINGS CO., LTD.	-6.93%	3.01B

Other Drug Retailers

Sopharma AD

Equities

SFA

BG11SOSOBT18

Drug Retailers

Sopharma : Insider information

Latest news about Sopharma AD

Chart Sopharma AD

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Drug Retailers